title: [Pioglitazone hydrochloride monotherapy or in combination with sulfonylurea therapy improves glycemia control in patients with type 2 diabetes].
abstract: OBJECTIVE
  To evaluate the clinical efficacy and tolerability of pioglitazone monotherapy or in combination with sulfonylurea therapy in the treatment of chinese patients with type 2 diabetes.
  
  
  METHODS
  This 12-week study involved 117 patients with type 2 diabetes whose blood glucose was uncontrolled on a stable regimen of diet or oral sulfonylureas for at least 3 months (fasting blood glucose (FBG) 7.8-15.0 mmol/L; postprandial blood glucose (PBG) >11.1 mmol/L)). The patients received once daily pioglitazone 30 mg plus diet (Group PIO-mono) or sulfonylurea (Group PIO-SU). The fasting and postprandial plasma glucose, serum insulin, C-peptid, lipid profile, free fatty acids (FFAs) levels were measured at baseline and every 4 weeks after treatment. Results All patients showed significant improvement in glycemic control over baseline. There were 1.64%, 2.1 mmol/L, 5.2 mmol/L decrease from baseline HbA1c, FBG and PBG levels in the Group PIO-mono and 1.06%, 2.3 mmol/L, 5.4 mmol/L decrease in the Group PIO-SU after 12 weeks treatment, respectivley. Both groups experienced slight decreases in C-peptide and insulin concentrations during 12 weeks period. Both groups showed mean percent decreases in triglyceride and FFA levels(21.8% and 20.7% for PIO-mono, 22.2% and 14.5 for PIO-SU) and increases in HDL-C (21.4% for PIO-mono and 30.8% for PIO-SU), compared with baseline. pioglitazone was well tolerated.
  
  
  CONCLUSIONS
  In patients with type 2 diabetes, pioglitazone monotherapy or in combination with sulfonylurea therapy significantly improves HbA1c, FBG and PBG levels and reserves the beta-cell function with beneficial effects on serum triglyceride and HDL-C levels.
authors.affiliation: Division of Endocrinology, West China Hospital, Sichuan University, Chengdu 610041, China.
authors.forename: Yerong
authors.initials: Y
authors.lastname: Yu
authors.forename: Yanbing
authors.initials: Y
authors.lastname: Li
authors.forename: Jiyuan
authors.initials: J
authors.lastname: Fan
authors.forename: Yan'gang
authors.initials: Y
authors.lastname: Wang
authors.forename: Honglin
authors.initials: H
authors.lastname: Yu
authors.forename: Chun
authors.initials: C
authors.lastname: Wang
authors.forename: Zhihong
authors.initials: Z
authors.lastname: Liao
authors.forename: Hua
authors.initials: H
authors.lastname: Gao
authors.forename: Wenjuan
authors.initials: W
authors.lastname: Zhao
mesh_terms: D000328:Adult; D000368:Aged; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D038321:Glycemic Index / Q000187:drug effects; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007333:Insulin Resistance; D008297:Male; D008875:Middle Aged; D000077205:Pioglitazone; D013453:Sulfonylurea Compounds / Q000008:administration & dosage*; D045162:Thiazolidinediones / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D000077205:Pioglitazone; D013453:Sulfonylurea Compounds; D045162:Thiazolidinediones